Marinus Pharmaceuticals (MRNS) to Release Quarterly Earnings on Thursday

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) will be announcing its earnings results before the market opens on Thursday, August 11th. Analysts expect Marinus Pharmaceuticals to post earnings of ($0.93) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) last posted its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.35. The company had revenue of $14.19 million during the quarter, compared to analysts’ expectations of $2.19 million. Marinus Pharmaceuticals had a negative net margin of 328.21% and a negative return on equity of 145.46%. On average, analysts expect Marinus Pharmaceuticals to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $5.38 on Thursday. The company has a 50-day simple moving average of $5.15 and a 200 day simple moving average of $7.35. The company has a debt-to-equity ratio of 1.94, a quick ratio of 6.91 and a current ratio of 6.91. The company has a market capitalization of $199.81 million, a price-to-earnings ratio of -2.18 and a beta of 1.43. Marinus Pharmaceuticals has a 52 week low of $3.97 and a 52 week high of $13.97.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals in the first quarter valued at about $317,000. Virtu Financial LLC bought a new position in Marinus Pharmaceuticals in the 1st quarter valued at approximately $221,000. MetLife Investment Management LLC boosted its position in Marinus Pharmaceuticals by 63.8% in the first quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 7,928 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Marinus Pharmaceuticals by 3.5% during the first quarter. Goldman Sachs Group Inc. now owns 156,949 shares of the biopharmaceutical company’s stock worth $1,468,000 after buying an additional 5,380 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Marinus Pharmaceuticals during the first quarter worth $40,000. 80.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 13th. Oppenheimer decreased their price target on shares of Marinus Pharmaceuticals to $28.00 and set a “na” rating on the stock in a research note on Monday, May 16th. JMP Securities reissued a “buy” rating and issued a $22.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, June 9th. Finally, Cantor Fitzgerald raised their target price on shares of Marinus Pharmaceuticals from $25.00 to $28.00 in a report on Wednesday, April 20th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.14.

Marinus Pharmaceuticals Company Profile

(Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Articles

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with's FREE daily email newsletter.